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Effects of Hypnotics on Sleep and Quality
of Life in Insomnia
Chris Alford and Sue Wilson
Summary This chapter provides an overview of the effects of hypnotics on sleep and quality of life (QOL). In the 1970s it
was accepted that a consequence of taking longer acting benzodiazepine hypnotics was a residual hangover next day, producing
feelings of sedation and impaired performance. The realization during the 1980s that insomnia was not just a subjective
complaint of poor sleep, but in itself resulted in impaired functioning with increased accident risk, led to studies evaluating the
effects of sleep medication on both sleep and waking function including QOL. The potentially impairing effects of hypnotic
treatment therefore need to be weighed up against the costs and consequences of untreated insomnia. The emergence of the
newer benzodiazepine receptor agonists (BzRAs) zopiclone, zolpidem and zaleplon (Z drugs) with their shorter half-lives and
reduced levels of residual impairment, tolerance and dependency, particularly for zolpidem and zaleplon, shift the balance in
favour of safer hypnotic treatment, so that insomnia should no longer go unrecognized and untreated in so many. Guidelines for
limiting hypnotic prescriptions to a few weeks resulted from the association of long-term benzodiazepine use with tolerance
and therefore lack of treatment benefit, as well as the associated risks of dependence occurring with some compounds. These
guidelines are at odds with the significant number of chronic insomniacs, often elderly patients, who require long-term treat-
ments. There is now limited evidence that newer formulations and different treatment schedules, including intermittent use,
can sustain hypnotic efficacy with the Z drugs over longer periods, enhancing QOL and waking function, and without rebound
insomnia following withdrawal. Similarly, behavioural and psychological approaches may be beneficial in the long term for
some, though possible treatment limitations amongst different types of patients have still to be defined.
Keywords Benzodiazepines · residual effects · accidents · newer benzodiazepine receptor agonist (Z-drugs) · improved
waking function · behavioural and psychological treatments
Learning objectives:
• Benzodiazepine hypnotics, particularly the longer
acting ones, are associated with residual impairments
of waking function next day.
• The elderly, in whom insomnia is more prevalent, are
more vulnerable to the impairing effects of benzodi-
azepines and are at greater risk of accidents and falls
as a result.
• Withdrawal of benzodiazepine and Z-drug hypnotics
can produce rebound insomnia.
• Benzodiazepine use is also associated with depen-
dency.
• Withdrawal from chronic benzodiazepine hypnotic
use is associated with improved waking function and
quality of life.
• Behavioural and psychological treatments are useful
for the treatment of chronic insomnia and withdrawal
from long-term benzodiazepine use.
• The newer benzodiazepine receptor agonists or ‘Z-
drugs’ have shorter half-lives and are associated with
reduced residual effects, particularly zaleplon and
zolpidem which are the shortest acting. However,
they may not be so effective for sleep maintenance
problems.
• Newer formulations of the Z-drugs (eszopiclone
and zolpidem-MR) may be effective for both sleep
initiation and maintenance problems, as well as
having reduced residual effects.
• The Z-drugs are associated with improved waking
function and quality of life in patients with insomnia.
From: J. C. Verster et al. (eds.): Sleep and Quality of Life in Medical Illnesses
c© 2008 Humana Press, Totowa, NJ
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Introduction
Looking back over the last 30 years to when the authors first
began in sleep research provides an interesting perspective
with which to evaluate the use and effectiveness of hypnotics
in the treatment of insomnia and their impact on quality of
life (QOL). Whilst earlier studies dating from the 1950s had
focussed on effects of these drugs on sleep, studies from the
1970s began to include assessment of residual effects next
day (1).
Research from the beginning of this period included assess-
ments of the then newer benzodiazepines, perhaps comparing
them to the older barbiturates. Studies typically involved
normally sleeping participants with sleep assessment largely
based on subjective measures and a variety of daytime perfor-
mance tests borrowed from the psychology laboratory to see
whether the sedative drugs were still impairing performance
next day (1–4). The view at this time was that residual impair-
ment may be a necessary result of effective hypnotic treat-
ment (2). Whilst benzodiazepines replaced the barbiturates
for safety reasons, shorter acting benzodiazepines such as
triazolam were then introduced in an attempt to limit the
morning ‘hangover’. Concerns over dependency, tolerance
and the search for shorter acting drugs producing less or
no residual impairments next day have resulted in the emer-
gence of the ‘Z’ drugs also described as the newer benzo-
diazepine receptor agonists (BzRAs). The first was zopi-
clone, followed by zolpidem and then zaleplon, each with
a shorter half-life. With zaleplon, a half-life of around 1 h
means that this drug can be taken during the night, up to
4 h before waking, without detectable residual impairments
(5, 6). This provides the opportunity for responsive treatment
as required rather than prophylactic administration ‘in case’
of a bad night. We have also seen the arrival of the first ‘non-
scheduled’ hypnotic in the USA, ramelteon, which is a mela-
tonin receptor agonist for use in sleep onset insomnia, and
developments continue with other GABAergic drugs which do
not act through the benzodiazepine receptor such as gabox-
adol (7) and tiagabine (8).
Has this evolution in hypnotic drugs met the needs of
insomniacs and the needs of physicians treating their patients?
If sleep can be improved has this solved any QOL problems
that may ensue as a result of poor sleep? Recent publications
indicate that the antidepressant trazodone is the most widely
prescribed drug used for the treatment of insomnia in the USA
and that hypnotic prescriptions have been falling over the last
decade (9, 10). This evidence alone suggests that the needs
of patients and physicians have not yet been met with the
‘perfect’ hypnotic as outlined by Bartholini nearly 20 years
ago (11).
This chapter provides an overview of the current situa-
tion regarding hypnotic treatment for insomnia, focusing on
health-related QOL aspects. A brief comparative review of
selected papers that look at the effect of hypnotics on the sleep
and waking performance in insomniacs is included. The final
sections look at the treatment of insomnia with hypnotics and
emerging alternative treatments, with a view to optimizing
QOL.
Who are the Patients?
Whilst most studies of hypnotics have employed ‘normal’
male volunteers, as is frequently the case in central
nervous system (CNS) drug development, insomniac patients
complain of problems sleeping, or poor sleep quality and
unrefreshing sleep, together with fatigue and tiredness and
impaired functioning during the day. In fact, impairment of
daytime function and impairment of related QOL aspects has
been used to aid assessment of severity and the decision to
treat this essentially ‘subjective’ complaint (12). Similarly, the
majority of insomniacs are women (13–15) with the preva-
lence increasing with advancing age (16–18), with up to a
quarter or a half of those aged 65 and older having insomnia
(18–20) although normative data indicate a median sleep dura-
tion of 7 h in the elderly (21). It is also worth noting that
the elderly are more affected by sleep maintenance problems
whilst the young suffer more from sleep initiation difficul-
ties (19) and this too has implications for hypnotic treat-
ment. Regrettably, the focus of hypnotic studies has not been
on the elderly or women rather than men. Epidemiological
studies suggest that somewhere around 10–15% of the popu-
lation have persistent or chronic insomnia (22–24). Figures
for insomnia and related sleep problems often suggest higher
figures of 30–40% (25–27) but may well reflect variability in
the criteria used to assess this condition where even a chronic
insomniac may not have problems sleeping every night. This
lack of a standardized definition has had a negative impact
when trying to compare studies of both pharmacological and
non-pharmacological treatment approaches though standard-
ized criteria have now been proposed and this should benefit
future research (28, 29).
What we do know is that hypnotic use reflects the greater
prevalence of insomnia in women rather than men and in
older rather than young adults (19, 30–38). Frighetto et al.
(17) reported that a third of patients, who were mostly in
their eighth decade, admitted to hospital had received antide-
pressants or hypnotics prior to hospital admission in their
Canadian study. Further, the elderly may have a greater need
for long-term treatment and may well be more vulnerable to
the impairing effects of sedative hypnotics drugs (16, 39, 40).
Whilst clinical guidelines generally indicate limited periods
for prescriptions (e.g. 2–4 weeks depending on the country),
14–35% of patients may have used them nightly over the
previous year (41).
It is also important to recognize that whilst nearly everyone
will experience some sleep disturbance in the course of a year
and some will continue to have sleeping difficulties for months
or years afterwards. When we carried out a local survey of
university employees with sleep problems, it indicated that
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approximately half of these respondents had their problem for
up to 6 months whilst the rest had a lasting problem, some up
to 20 years. The Europe-wide SOFRES study found a median
duration of 2–6 years (42). The long durations reported for
insomnia led Epstein and Bootzin (43) to proclaim that these
long suffering patients were ‘in dire need of treatment’. This
raises further questions of why should insomnia persist so
long in those who develop chronic insomnia and are hypnotics
of any use for long-term treatment?
Several authors have pointed out that patients, including
the elderly, may not report their insomnia to their healthcare
providers, and consequently the condition may not be recog-
nized and will go untreated (18, 31, 44, 45). Sateia et al. (46)
reported that between 30 and 80% of patients show no signif-
icant remission over time and that 70% of patients do not
discuss their problem, a finding supported by Kageyama et al.
(31), who suggested that 80% of Japanese insomniacs were
untreated. Having witnessed the concern over benzodiazepine
dependency in the 1980s, including public demonstrations in
Europe, it was hardly surprising to see that hypnotic prescrip-
tions fell from 1970 to 1989 reflecting these concerns and
those of the prescribing physicians (47) although higher rates
may be seen in some countries with Byles and colleagues
reporting that in Australia half of their sample of older women
with sleeping problems were receiving medication in the
last month (30). These concerns and the resulting limitations
imposed on treatment duration may partially explain why
prescription hypnotics are not the most used or prescribed
treatments for insomnia and why the antidepressant trazodone
is the most widely prescribed ‘hypnotic’ in the USA (9)
despite a relative lack of appropriate studies demonstrating
efficacy (9,10,40). This in itself is remarkable given the seda-
tive nature of this drug and its impairing effects on perfor-
mance and impairment of sexual function (48, 49).
The association between insomnia and depression may in
part help to account for the widespread use of trazodone
although the use of sub-therapeutic doses of antidepressants
as hypnotics may also result from the reluctance to use benzo-
diazepines long term although studies of their efficacy are
more limited (10, 24, 40, 50–52). Thase (10) points out that
ideally monotherapy would be used to treat both insomnia
and depression, although at present no suitable drug exists.
The close links between mental disorders such as anxiety
and depression and insomnia emphasizes the need for appro-
priate treatment, half of patients with chronic insomnia have
a primary psychiatric disorder such as anxiety or depres-
sion (10, 53). Insomnia has been considered as a possible
prodromal phase for depression and although authors stop
short of claiming that insomnia causes depression, the fact
that untreated insomnia increases the likelihood of developing
clinical depression is clearly established (54–57). Similarly,
improvement in depression may parallel improvements in
insomnia (10,58–60) though this may reflect a negative cogni-
tive bias associated with depression itself (61, 62). Subjec-
tive sleep improvement has also been linked to phase-shifts in
sleep for these patients (63). However, these links should be
considered when evaluating the effects of hypnotics on QOL
and the relative merits of hypnotic treatment.
Before looking at the specific effects of hypnotics on rele-
vant QOL aspects including mood and performance, it is
useful to briefly consider the effects of insomnia itself on
QOL, though fully described elsewhere in this volume, to
provide a comparison. If hypnotics have negative effects, then
is it worth using them or would it be better to leave insomnia
untreated? Following on are the questions of whether all
hypnotics are the same and how do they compare to other
treatments?
What are the Costs and Consequences
of Insomnia?
Whilst early studies of benzodiazepines focussed on their
potential to improve sleep and possibly their effects on waking
performance next day, there was a shift in research during the
last decade recognizing the importance of health-related QOL
and its relevance when considering insomnia and disturbed
sleep (64, 65). The wake up call probably came in 1988 when AQ1
Damien Leger published figures suggesting that of the US
accident costs for 1988 ($50 billion) around a third may
be sleep related (66). This helped to focus attention on the
wider significance of sleep disorders as well as their treatment.
There have been a range of estimates for the annual costs of
insomnia including $14 billion direct costs and $80 billion
for indirect costs (67, 68), and $30–35 billion by Chilcott
and Shapiro (69) comprising direct costs (health care provi-
sion) and indirect costs such as absenteeism and accidents
(70,71). Consequently, there is now the realization that there is
a critical duration of sleep needed to ensure health and safety
(72, 73).
These figures alone show that it is important to treat
insomnia as the cost to both patients and society will in turn
affect QOL through reducing available resources. Further,
the finding that falls in the elderly are related to insomnia
and tiredness is important to bear in mind when consid-
ering the relative merits of hypnotic treatment (74). General
costs and consequences include increased daytime sleepiness
and fatigue leading to cognitive impairment and poor work
performance and absenteeism in addition to increased acci-
dent risk including driving, increased risk of new or recur-
rent psychiatric disorder and increased substance use, poorer
prognosis, increased healthcare-related financial burden and
poorer social functioning at work and at home (10, 13, 22, 24,
55, 66, 68, 70, 75–77).
Apart from the more drastic consequences of insomnia with
daytime sleepiness and fatigue resulting in impaired perfor-
mance and accidents, recent research has indicated the role
of sleep in memory consolidation (78), and this may partially
explain the association of disturbed and insufficient sleep with
poorer academic performance (79, 80). Recently, two groups
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have shown a relative impairment in memory consolidation
for insomniacs in comparison to normal sleepers (81, 82).
The ‘SF-36’ is perhaps the most well-known questionnaire-
based QOL measure used in insomnia research though
several exist including a specific ‘quality of life in insomnia’
(QOLI) scale (83). However, Buysse and colleagues recently
described the use of the SF36 as ‘essential’ for insomnia
research (28). The SF36 comprises eight dimensions: phys-AQ2
ical and social functioning, role physical and mental,
energy/vitality, pain, mental health and health perceptions.
The authors were involved in evaluating the findings of
Europe-wide SOFRES study (42, 84), which indicated reduc-
tions for role physical, energy, vitality and mental health.
These reductions fell outside the normal ranges established for
the SF36 (85). These findings were supported by the signif-
icant reductions in emotional, social and physical domains
found by Zammit et al. (86). Several studies have found reduc-
tions in QOL dimensions associated with insomnia, including
greater reductions in SF36 with increased severity of insomnia
for physical and social functioning, energy/vitality, mental
health and general health perceptions (24, 87). This increased
reduction in QOL with increased severity of sleep prob-
lems has also been observed for older women insomniacs
(30), the patient group in whom insomnia is most prevalent.
Research with other instruments has indicated increased func-
tional impairment and healthcare costs in insomnia (88) and
associated reductions in QOL (25, 45). A reduced QOL in the
elderly with insomnia has also been reported (34, 36).
Taken together, these findings show that insomniacs are not
just troubled by inadequate or un-refreshing sleep, with conse-
quent feelings of tiredness and fatigue during the day, but that
this in turn translates into significant health risks and costs,
with poorer life performance affecting both work and home.
Further, there is a significant financial burden attached as well
as increased injury and mortality as a result of accidents. It is
then remarkable that insomnia frequently goes unreported or
untreated.
Do Hypnotics Improve Waking Function?
Given the above, there is a clear imperative to treat insom-
niac patients, whether they are primary insomniacs or whether
their insomnia is related to another illness or associated with
a mental health problem.
The earlier studies investigating benzodiazepines
clearly established the residual effects associated with
benzodiazepine use, particularly for the longer acting
compounds or those with long-acting metabolites. Not only
did the morning ‘hangover’ affect mood and subjective feel-
ings of alertness but aspects of performance including speed
of psychomotor response as well as memory were impaired
(89–94). These findings, presented in numerous publica-
tions, together with concerns over dependency and tolerance
associated with some chronic benzodiazepine usage and the
realization that their continuous use did not improve the
sleep of insomniacs and that withdrawal may itself produce
insomnia and related adverse effects (95–103) led to the
development of the newer benzodiazepine receptor agonists
or BzRAs, zopiclone, zolpidem and zaleplon by the pharma-
ceutical industry (104–107). In comparison to the traditional
benzodiazepines, these compounds are associated with a more
natural sleep profile, e.g. without the reductions in slow wave
sleep seen with benzodiazepines (50) and generally associ-
ated with a lower abuse potential and less residual effects,
particularly zolpidem and zaleplon (23, 44, 108–111), leading
to improvements in insomnia management (112).
Accidents and Car Driving
Laboratory performance assessments provide useful direct
comparisons and models of every day life with which to
compare a therapeutic class of compounds such as hypnotics.
However, possible real life dangers associated with hypnotic
consumption may be reflected in accident figures and driving
assessment. Increased traffic accident risks have been associ-
ated with benzodiazepine use and an increased risk has also
been found with zopiclone. Similarly, increased falls and asso-
ciated injuries as well as increased traffic accidents have been
linked to benzodiazepine use in the elderly (113–122).
The increasingly shorter half-lives for zopiclone (over 4 h),
zolpidem (2 h) and zaleplon (1 h) have been reflected in their
relative degree of residual impairment. The traditional benzo-
diazepines, particularly those with longer half-lives and longer
acting metabolites are associated with greater impairment and
sustained residual effects (23, 123–125). However, reviews
also indicate that some of the shorter acting compounds
are not associated with the same degree of impairment. For
example, Puca et al. (126) reported improved sleep and QOL
and no residual effects with triazolam given to shift-work
syndrome patients.
The elderly are more vulnerable to the impairing effects
of sedative drugs, particularly the longer acting ones, yet
they receive more benzodiazepines and with more chronic use
(35, 36–38, 39), and this is also reflected in falls and related
injuries. Stein and Barrett-Connor (127) reported a reduc-
tion in QOL in the elderly associated with the use of medi-
cation including hypnotics that went beyond the impact of
the comorbid illness. On the other hand, Ring (18) reviewed
chronic insomnia in the elderly and noted that early recogni-
tion and treatment of insomnia would increase QOL, particu-
larly as the condition is under-recognized in these patients.
When compared with the lower incidence of side effects
in general for the Z-drugs and substantial lack of residual
effects for zaleplon and zolpidem in particular, then a clear
distinction can be made (23, 128–130). Recent reviews of
driving studies have shown that both zaleplon and zolpidem
lack residual effects when assessed with both simulated and
on the road driving (131, 132). Given the clear association
between insomnia, increased tiredness, sleep loss and driving
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7. Effects of Hypnotics on Sleep and Quality of Life in Insomnia 53
accidents (75, 77, 133), the lack of residual impairments in
driving performance next day is an important indicator of
the potential benefits of zaleplon and zolpidem on functional
aspects of QOL.
The introduction of the newer BzRAs or Z-drugs has
therefore provided something of a watershed in relation to
pharmacotherapy for insomnia. The older benzodiazepines
were frequently associated with residual impairments next
day, which had a negative impact on QOL affecting waking
mood, work performance and accident risks. The elderly in
whom insomnia and benzodiazepine use is increased are most
vulnerable here, with reduced hepatic clearance and other age-
related impairments potentially exacerbating residual effects.
Studies of the effects of the Z-drugs on sleep, daytime alert-
ness and performance, or related QOL aspects in insomniacs
show that they are not associated with the degree of impair-
ment seen with the benzodiazepines. Goldenberg et al. (134)
reported significantly improved QOL in insomniacs after 2
weeks zopiclone in comparison to placebo. Leger, Quera-
Salva and Philip (135) looked at both short- and long-term
administration of zopiclone in insomniacs. Both sleep and
QOL were improved at 8 weeks against placebo. No signifi-
cant differences were found for patients who had been taking
zopiclone for 12 months when compared to controls without
sleep problems on nearly all QOL measures, suggesting that
QOL can be normalized in insomniacs given appropriate
hypnotics.
An investigation of eszopiclone, the (S)-isomer of racemic
zopiclone, in elderly insomniacs revealed improved sleep,
increased daytime alertness, physical well-being and other
QOL variables, in addition to reduced napping (136). This
contrasts with reductions in QOL found in insomniacs with
increased daytime sleepiness and napping (25), demonstrating
the ability of Z-drugs to promote a functional increase in
daytime alertness when given to insomniacs. Soares et al.
(137) found that eszopiclone improved both subjective sleep
and QOL in women insomniacs. These brief examples demon-
strate the ability of Z-drugs to both improve sleep and improve
waking function when given to insomniac patients, including
both short and long-term administration.
The results of systematic reviews of sleep, performance
and related QOL measures with strict inclusion criteria,
contrasting traditional benzodiazepines and the newer Z-drugs
in carefully controlled patient trials have not been able to
make firm conclusions due to the limited number of studies
compared (138).
Studies of daytime function using psychomotor
performance tests in healthy volunteers after hypnotic drug
administration have been very useful in indicating behavioural
toxicity, as seen above, and impairments have been seen after
single doses of even short-acting agents. However, similar
measures in insomniac patients have been less conclusive.
Table 7.1 summarizes controlled studies of hypnotic drug
effects on performance in patients. This includes some tradi-
tional benzodiazepines, the newer Z-drug hypnotics, as well
as single examples for the GABA agonist tiagabine and mela-
tonin agonist ramelteon. The studies in the table reflect the
general findings from past research where the benzodiazepine
flurazepam was deliberately chosen as a comparator for
newer compounds as it is has the longest half-life (up to 250
h) and can serve as a positive control. Flurazepam reliably
impairs performance next day whilst the Z-drugs or short-
acting benzodiazepines may not although simulated driving
performance was impaired by zopiclone as mentioned earlier.
Whilst reliable deficits were seen with flurazepam other find-
ings are less consistent than those in healthy volunteers. One
explanation may be that these patients differ markedly from
controls at baseline, in that they complain of fatigue, dimin-
ished motivation, cognitive dysfunction including reduced
vigilance, memory and concentration, low mood and various
physical complaints so that impairing effects of drugs may be
less obvious. It may be that as these patients had been taking
the treatment for some days or weeks, early impairment may
have worn off by the time of testing.
Though limited in number, these studies endorse the
conclusions made above that the newer Z-drugs are less
impairing than older long-acting compounds, favouring their
use over the older benzodiazepines with their related depen-
dency, tolerance and withdrawal problems. To date, studies
with the newer agonists tiagabine and ramelteon have been too
few to draw specific conclusions.
Sleep Initiation and Maintenance
Given the variability in both the frequency of occurrence
of disturbed sleep, as well as patient differences relating to
problems in initiating sleep, maintaining sleep or waking
early, it is important to consider which hypnotics are most
suited to aiding sleep onset and which can also maintain
sleep. With the benzodiazepines, longer acting compounds
produced consistent residual impairment leading to the search
for shorter acting but less impairing compounds on waking
performance next day (139). This has been reflected in the
development of the Z-drugs with even shorter half-lives.
Whilst they produce less residual impairment, there is a trade-
off resulting in reduced efficacy of the shorter acting zale-
plon (1 h half-life) and zolpidem (2 h half-life) with regard
to sleep maintenance. On the other hand, zopiclone (>4 h
half-life) may produce significant waking impairment but is
more appropriate for sleep maintenance problems (10, 40).
The newer derivatives may be a response to this. Eszopiclone
may promote sleep maintenance but with reduced potential for
impairment, whereas modified release zolpidem (zolpidem-
MR) may also increase sleep duration though studies are
currently limited (136,140–142). The limitation of the shortest
acting Z-drugs zaleplon and zolpidem in treating sleep main-
tenance problems is a potentially significant drawback to their
use. It is also worth reflecting that more sleep onset insomnia
UN
CO
RR
EC
TE
D 
PR
OO
F
01
02
03
04
05
06
07
08
09
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55 Ta
b
le
7.
1.
Co
n
tr
o
lle
d
st
u
di
es
o
fh
yp
no
tic
dr
u
gs
in
in
so
m
n
ia
.
Re
fe
re
n
ce
D
es
ig
n
Pa
tie
nt
s
N
D
ru
g
N
o.
o
fn
ig
ht
s
Im
pr
ov
ed
sle
ep
?
Te
st
tim
e
(ho
urs
af
te
r
do
sin
g)
Te
st
s
Pe
rfo
rm
an
ce
re
su
lts
17
5
D
B
II
gr
ou
p
3/
12
in
so
m
n
ia
30
Zo
pi
cl
on
e
7.
5
m
g,
flu
ra
ze
pa
m
30
m
g,
pl
ac
eb
o
10
Y
(su
bj)
11
D
SS
T
im
m
ed
ia
te
an
d
de
la
ye
d,
re
ca
ll,
m
o
v
em
en
t
Fl
u
ra
ze
pa
m
-
im
pa
ire
d
m
o
v
em
en
t
17
6
D
B
II
gr
ou
p
El
de
rly
in
so
m
n
ia
cs
36
B
ro
tiz
ol
am
0.
25
m
g,
flu
ra
ze
pa
m
30
m
g
14
Y
(su
bj)
12
D
SS
T
im
m
ed
ia
te
an
d
de
la
ye
d,
re
ca
ll,
m
o
v
em
en
t
B
ot
h
dr
ug
si
m
pa
ire
d
al
l(
au
th
or
s
co
m
m
en
td
os
es
to
o
hi
gh
).
Im
pa
irm
en
t
re
co
v
er
y
pr
op
or
tio
na
lt
o
ha
lf-
lif
e
17
7
Si
ng
le
-b
lin
d
Ch
ro
ni
c
in
so
m
n
ia
(al
lh
ad
pa
st
hy
pn
ot
ic
s)
6
Pl
ac
eb
o
ru
n
-in
,
zo
lp
id
em
10
m
g
14
Y
8.
5
M
em
o
ry
,
m
an
u
al
de
x
te
rit
y,
m
az
e,
D
SS
T
N
o
im
pa
irm
en
t
17
8,
17
9
D
B
II
gr
ou
p
Ch
ro
ni
c
in
so
m
n
ia
,
re
cr
u
ite
d
by
ad
ve
rt
ise
m
en
t
10
7
Pl
ac
eb
o
ru
n
-in
flu
ra
ze
pa
m
15
m
g,
20
m
g
m
id
az
ol
am
15
m
g
14
9
D
SS
T,
v
ig
ila
nc
e,
di
v
id
ed
at
te
nt
io
n,
m
o
o
d
Fl
u
ra
ze
pa
m
20
m
g
im
pa
ire
d
al
l,
sli
gh
t
im
pa
irm
en
tw
ith
15
m
g,
n
o
n
e
w
ith
m
id
az
ol
am
18
0
D
B
PC
II
gr
ou
p
In
so
m
n
ia
,u
n
ab
le
to
sle
ep
w
ith
ou
t
m
ed
ic
at
io
n
26
Zo
pi
cl
on
e
7.
5
m
g
o
r
flu
ra
ze
pa
m
30
m
g
o
r
pl
ac
eb
o
35
N
o
ts
ta
te
d
CF
F,
CR
T,
di
gi
ts
pa
n
CR
T
an
d
di
gi
ts
pa
n
im
pa
ire
d
by
flu
ra
ze
pa
m
18
1
D
B
5-
w
ay
II
gr
ou
p
A
ge
65
+
D
SM
III
R
in
so
m
n
ia
w
ith
TS
T
<
5
ha
nd
/o
r#
w
>
3
fo
r
3
m
o
n
th
s
45
Te
m
az
ep
am
15
an
d
30
m
g,
tr
ia
zo
la
m
12
5
an
d
25
0
µ
g,
pl
ac
eb
o
Si
n
gl
e
do
se
12
W
ec
hs
le
r
v
er
ba
lm
em
o
ry
ta
sk
s,
D
SS
T,
tr
ai
l-m
ak
in
g,
fin
ge
r-t
ap
pi
ng
o
n
m
o
rn
in
gs
be
fo
re
an
d
af
te
rd
os
e
n
ig
ht
Si
gn
ifi
ca
n
ti
m
pa
irm
en
t
w
o
rd
pa
ir
re
ca
ll
w
ith
hi
gh
do
se
s,
sig
ni
fic
an
t
im
pr
ov
em
en
t
tr
ai
l-m
ak
in
g
af
te
r
lo
w
do
se
,
hi
gh
do
se
n
o
ch
an
ge
AQ
3
UN
CO
RR
EC
TE
D 
PR
OO
F
01
02
03
04
05
06
07
08
09
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55 T
a
b
le
7.
1.
Co
n
tin
u
ed
Re
fe
re
n
ce
D
es
ig
n
Pa
tie
nt
s
N
D
ru
g
N
o.
o
fn
ig
ht
s
Im
pr
ov
ed
sle
ep
?
Te
st
tim
e
(ho
urs
af
te
r
do
sin
g)
Te
st
s
Pe
rfo
rm
an
ce
re
su
lts
18
2
D
B
PC
II
gr
ou
p
3/
12
in
so
m
n
ia
68
Zo
lp
id
em
10
m
g,
15
m
g,
pl
ac
eb
o
35
N
o
ts
ta
te
d
D
SS
T
N
o
ef
fe
ct
s
(ve
ry
lit
tle
su
bje
cti
v
e
ef
fe
ct
,
sm
al
lo
bje
cti
v
e
ef
fe
ct
o
n
sle
ep
)
13
4
D
B
PC
II
gr
ou
p
R
ec
ru
ite
d
th
ro
ug
h
m
ar
ke
t
re
se
ar
ch
o
rg
an
iz
at
io
n,
TS
T
<
6
h,
SO
L
>
30
m
in
23
1/
22
7
Zo
pi
cl
on
e
7.
5
m
g,
pl
ac
eb
o
14
N
A
QO
L,
su
bje
cti
v
e
sle
ep
QO
L
im
pr
ov
ed
bo
th
gr
ou
ps
,
sig
ni
fic
an
tly
m
o
re
in
zo
pi
cl
on
e
gr
ou
p,
in
da
ily
ac
tiv
iti
es
,
so
ci
al
an
d
pr
of
es
sio
n
al
su
bs
ca
le
s
18
3
D
B
PC
CO
Pr
im
ar
y
in
so
m
n
ia
(ve
ry
sim
ila
rt
o
D
SM
IV
cr
ite
ria
)
23
F
Zo
lp
id
em
10
m
g,
te
m
az
ep
am
20
m
g,
pl
ac
eb
o
at
02
.0
0
30
5.
5
D
riv
in
g
sim
u
la
to
r
07
.3
0
fo
llo
w
ed
by
im
m
ed
ia
te
re
ca
ll
m
em
o
ry
te
st
N
o
sig
di
ffs
al
th
ou
gh
a
fe
w
in
di
v
id
ua
l
su
bje
cts
’
dr
iv
in
g
af
fe
ct
ed
ba
dl
y
by
bo
th
dr
u
gs
—
m
ay
be
es
pe
ci
al
ly
v
u
ln
er
ab
le
pe
op
le
?
N
o
ef
fe
ct
o
n
m
em
o
ry
te
st
s
18
4
D
B
PC
II
gr
ou
p
D
SM
-IV
pr
im
ar
y
in
so
m
n
ia
,T
ST
<
7h
,S
O
L
>
20
m
in
30
8
Es
zo
pi
cl
on
e
2,
3
m
g,
pl
ac
eb
o
44
1–
1.
5
h
af
te
r
w
ak
en
in
g
D
SS
T
N
o
sig
ef
fe
ct
13
2
D
B
PC
4-
w
ay
CO
D
SM
-IV
pr
im
ar
y
in
so
m
n
ia
,
re
cr
u
ite
d
by
ad
ve
rt
ise
m
en
t
23
Zo
lp
id
em
10
m
g,
zo
pi
cl
on
e
7.
5
m
g,
lo
rm
et
az
ep
am
1
m
g,
pl
ac
eb
o
7
2
h
af
te
r
w
ak
in
g
D
riv
in
g
sim
u
la
tio
n
Lo
rm
et
az
ep
am
-
im
pa
ire
d
sp
ee
d
de
v
ia
tio
n
an
d
sp
ee
d
lim
it
de
v
ia
tio
n.
Zo
pi
cl
on
e
in
cr
ea
se
d
n
u
m
be
ro
fc
o
lli
sio
ns
8
D
B
PC
CO
D
SM
-
IV
pr
im
ar
y
in
so
m
n
ia
,
re
cr
u
ite
d
by
ad
ve
rt
ise
m
en
t
Ti
ag
ab
in
e
4,
8,
12
,
16
m
g,
pl
ac
eb
o
2
A
bo
ut
an
ho
ur
af
te
r
w
ak
in
g
D
SS
T
an
d
R
ey
au
di
to
ry
le
ar
ni
ng
te
st
D
SS
T
im
pa
ire
d
by
8
an
d
16
m
g
18
5
D
B
PC
CO
Tr
ea
tm
en
t
se
ek
in
g
pl
us
ad
ve
rt
ise
m
en
t
10
7
R
am
el
te
on
4,
8,
16
,3
2
m
g,
pl
ac
eb
o
26
N
o
ts
ta
te
d
D
SS
T,
w
o
rd
-li
st
im
m
ed
ia
te
an
d
de
la
ye
d
re
ca
ll
N
o
ef
fe
ct
s
#w
,
n
u
m
be
ro
fa
w
ak
en
in
gs
;C
FF
,
cr
iti
ca
lfl
ic
ke
r
fu
sio
n
fre
qu
en
cy
;C
O
,
cr
o
ss
o
v
er
;C
RT
,
ch
oi
ce
re
ac
tio
n
tim
e;
D
SS
T,
di
gi
ts
ym
bo
ls
u
bs
tit
ut
io
n
te
st
;I
Ig
ro
u
p,
pa
ra
lle
lg
ro
u
p;
PC
,
pl
ac
eb
o
co
n
tr
o
lle
d;
RT
,
re
ac
tio
n
tim
e;
SO
L,
sle
ep
o
n
se
tl
at
en
cy
;T
ST
,
to
ta
ls
le
ep
tim
e.
UN
CO
RR
EC
TE
D 
PR
OO
F
01
02
03
04
05
06
07
08
09
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56 Alford and Wilson
is seen in younger insomniacs whilst sleep maintenance prob-
lems are more prevalent in the elderly who in turn are more
vulnerable to the effects of impairing drugs (19).
Treatment Regimens
Concerns over dependency and loss of efficacy after contin-
uous treatment with benzodiazepines led regulatory authori-
ties to impose clinical guidelines limiting prescriptions. Given
the epidemiological data indicating that 10–15% of the popu-
lation suffer from chronic insomnia and the need of some,
including elderly patients for prolonged treatment, treatment
guidelines are clearly at odds with patient needs. The develop-
ment of the newer BzRAs, with a more favourable side effects
profile, including reduced dependency potential for some
compounds, suggests that guidelines predicated on the benzo-
diazepines may now be out of date and that longer treatment
periods should be considered (14, 24, 143). Sadly, the dura-
tion of most controlled studies is relatively short, one meta
analysis found a median treatment duration of just 7 days,
whereas chronic insomniac patients sometimes use hypnotics
for months to years (144,145). Although few in number, some
longer term treatment studies have been undertaken. Patient
studies with zolpidem have revealed overall improvements
(146–149). In a 17-week study of zopiclone, Fleming, Bour-
gouin and Hamilton (150) failed to find evidence of tolerance,
whereas a study of eszopiclone in chronic insomniacs (141)
revealed both sustained sleep improvements as well increased
alertness and functioning during the day, but without adverse
side effects or tolerance over the 6-month study period. A 12-
month extension of the study showed comparable efficacy and
safety (151). A shorter 5-week assessment of zaleplon (152)
found that sleep latency was reduced across treatment weeks,
although consistent increases in total sleep time were not seen.
There was no evidence of tolerance or rebound insomnia seen
on initial withdrawal.
Intermittent treatment has also shown promising results.
Intermittent treatment with the benzodiazepine triazolam
found reduced self-administration when compared to nightly
or as needed treatment regimens (153). Although an 8-week
comparison of zolpidem against placebo found improved
sleep but failed to reveal significant differences for QOL,
a multi-centre 2-week comparison of nightly against 5 out
of 7 nights dosing revealed marked QOL improvements
in both chronic insomniac treatment groups (154, 155). A
more recent review of six patient studies with intermittent
zolpidem administration found that sleep improved without
adverse effects and hypnotic consumption was not increased.
Some studies recorded improvements in QOL measures (44).
Studies with zaleplon have indicated the lack of impairment
next day with zaleplon when administered during the night,
and this might also offer a new treatment regimen where
patients can use the drug not only intermittently but on a
symptomatic rather than prophylactic basis, waiting to see
whether they can fall asleep naturally before taking a hypnotic
(5, 6, 23).
Taken together, these studies of long-term and intermit-
tent treatment regimens with the newer BZRAs or Z-drugs
suggest that not only can the sleep of chronic insomniacs
be improved for sustained periods but waking function and
related QOL measures may also be improved. The lack of
evidence for dependency or tolerance in these studies implies
clinical guidelines might be updated supporting longer admin-
istration with associated benefits in QOL. This would help
meet the needs of patients who require long-term treatment
(10, 40).
Other Treatments for Insomnia
Prescription hypnotics are in a minority when compared to
the range of treatments used by insomniacs. The widespread
use of trazodone and antidepressants as ‘hypnotics’ has been
mentioned. Other popular pharmacologically based treat-
ments include over-the-counter (OTC) antihistamines, herbal
remedies, l-tryptophan, melatonin and aromatherapy (9, 10,
40, 108) although alcohol is also popularly self-administered
in the West despite cost, tolerance and toxicity (156). There
are also a wide variety of other methods employed including
psychological and behavioural therapies, bright light and
relaxation therapy as examples. Whilst a fuller evalua-
tion of these cannot be included here, a brief mention is
appropriate.
There is limited evidence that OTC antihistamines work
although recently some benefits have been reported for
diphenhydramine (157). More profound effects on sleep
have been reported for both promethazine and hydroxyzine
although neither are available as OTC hypnotics (158–160).
A recent review of melatonin shows promise for its use for
circadian and sleep-phase disorders including shift work (161)
although evidence for its use in insomnia is less positive (162).
Several herbal remedies have been investigated, and interest
in these compounds is growing though published studies are
few (163). Valerian or valerian and hops are popular in some
herbal OTC remedies but findings are varied with Morin
et al. (157) observing benefits in mild insomnia with vale-
rian and hops whilst Diaper and Hindmarch (164) failed to
find significant effect on sleep and performance with vale-
rian alone. A recent review of 16 studies suggested that vale-
rian might improve sleep quality without concomitant side
effects (165). Similarly, there is some evidence emerging that
aromatherapy may be useful, for example a study by Goel
et al. (166) found that lavender not only improved sleep but
also increased slow wave sleep which may be of particular
benefit to the elderly whose slow wave sleep is reduced.
Lewith et al. (167) have found that lavender oil reduced mild
insomnia, and Komori et al. (168) found mixed fragrance
assisted withdrawal from long-term benzodiazepine use in
insomniacs.
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Whilst more controlled studies are required for these alter-
native or complementary remedies, if efficacious, they may
offer some advantages. Unlike many prescription medica-
tions, they may have reduced side effects and residual impair-
ments next day. This is of particular importance for the elderly
who may require longer treatment and who frequently suffer
from other illnesses that may require medicines. Therapies
that are free from adverse side effects, and possible drug inter-
actions, may be of particular benefit and significantly improve
not only sleep but resulting QOL.
Cognitive and behavioural therapies (CBT) are worth
particular mention as there benefits are being increasingly
recognized although they may not be suitable for all insom-
niac patients (10,40). The negative effects of long-term benzo-
diazepine treatment, particularly in the elderly, has been
outlined. Withdrawing patients can therefore provide benefits.
In a study of elderly long-term benzodiazepine users in whom
over 60% had continuously used their hypnotics for over 10
years, 80% were successfully withdrawn from their treatment
at 6 months after tapering their dose. The withdrawers showed
improved waking performance in comparison to the contin-
uers but showed little by way of sleep differences or with-
drawal problems (95).
Studies using CBT have also been successful in helping
withdraw long-term benzodiazepine users from treatment and
in maintaining improved sleep. Dixon, Morgan and colleagues
noted decreased QOL at baseline in long-term hypnotic users,
although the decrement reduced with advancing age (169,
170). At 3 and 6 months, sleep and QOL were improved, with
sleep improvements and reduced hypnotic use maintained at
12 months follow-up. Reviews by Morin and colleagues has
emphasized the reliable and durable effects that can result
from behavioural treatments (171, 172), with Epstein and
Bootzin (43) emphasizing that non-pharmacological treat-
ments can make a substantial contribution to QOL for insom-
niacs. Authors have pointed out that the psychological and
behavioural treatment approach takes time, as well as signif-
icant resources which may balance over long-term treatment,
so that efficacy is delayed in comparison to drugs that may
be more appropriate for short-term treatments. Further, not
all patients may be suitable for CBT approaches, Morgan
and colleagues found that patients with higher levels of
distress at onset had poorer outcomes (10, 16, 40, 170, 173).
Similarly, McCrae et al. +174) found that sleep hygiene
practices did not differ between good and poor elderly
sleepers suggesting this approach may have limitations in the
elderly.
Conclusion
The current interest in medicinal treatments and QOL reflects
developments in psychopharmacology. Where as past treat-
ments were focussed on reducing deficits, present research
looks more toward optimizing function and even enhancing
performance. Thirty years ago, it may have been sufficient to
treat disturbed sleep and insomnia with a sedative hypnotic
compound and accept residual impairments next day as a
consequence of improving sleep. Newer hypnotic compounds
including the Z-drugs provide us with important treatment
options when weighing up the cost benefit ratio for a partic-
ular patient. We know that prolonged and untreated insomnia
is associated with impaired QOL as well as substantial costs
to society as a result of direct health costs and indirect costs
through accidents and absenteeism. Although the shortest
acting of the Z-drugs may not be suitable for treating sleep
maintenance problems, they show significantly reduced side
effects and residual impairments, with improved QOL, and
should be promoted over the older benzodiazepines as appro-
priate drug treatments for insomnia (113). The emerging
hypnotics and newer formulations for the Z-drugs (eszopi-
clone and zolpidem-MR) hold promise for treating both sleep
onset and sleep maintenance problems without compromising
QOL, and prolonged treatment may now be acceptable.
Where possible, long-term drug treatment for insomnia
should be avoided, with cognitive and behavioural thera-
pies providing useful alternatives and aiding withdrawal from
long-term benzodiazepine use resulting in improved sleep and
QOL. However, the range of application and possible treat-
ment limitations of these treatment approaches needs to be
further explored. Similarly, studies of alternative and comple-
mentary therapies need progressing to establish the efficacy
and range of application for treatments such as herbals and
aromatherapy.
With the current range of hypnotic treatments, there is no
longer an excuse for insomnia to go unreported and unrec-
ognized and untreated in so many patients including the
elderly. Further, shorter-term insomnia should be treated to
help prevent the transition to chronic insomnia with its asso-
ciated marked impairments in quality of life.
Issues that need to be addressed by future research:
• Further studies are required to assess the impact of
long-term administration of the Z-drug hypnotics on
sleep and waking function in chronic insomniacs,
including the elderly.
• The range of patients and types of insomniacs that
are effectively treated with behavioural and psycho-
logical therapies needs to be established.
• The effectiveness of alternative therapies including
aromatherapy and herbal remedies needs to be
established but may provide useful alternatives to
prescribed hypnotics.
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Query No. Page No. Line No. Query
AQ1 51 23 The references are been renumbered in order to maintain sequential order. Please check.
AQ2 52 08 The sentence ”The SF36 comprises eight dimensions” states that there are eight dimensions. But only six
seem to be listed. Please check.
AQ3 53 Table 1 Please clarify whether the text “(authors comment doses too high)” should be deleted from the table.
AQ4 58 37 Please update the page ranges for reference 12.
AQ5 60 47 Please update the page ranges for reference 98.
AQ6 61 51 Please update reference 134.
